Mounjaro and Inflammation/inflammatory conditions?

By Gwynne Sullivan, Amy Nowacoski · last reviewed May 9, 2026

Adapted from the Mounjaro for Diabetes FAQ with permission from the contributing authors.

Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control Mediators Inflamm, 2016 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823510/

“The clinical effect observed and the direct interaction between GLP-1 and the immune system raise the possibility of therapeutic applications for GLP-1 in inflammatory conditions such as psoriasis.” Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis Diabetologia, November 2011 https://pubmed.ncbi.nlm.nih.gov/21744074/

“Adiponectin significantly increased from baseline with tirzepatide compared with placebo (10, 15 mg).” From here: Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes Diabetes Care, April 2020 https://diabetesjournals.org/care/article/43/6/1352/35649/Effects-of-Novel-Dual-GIP-and-GLP-1-Receptor See here for more about the role of adiponectin: Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction International Journal of Molecular Sciences https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486142/